Literature DB >> 16409165

New treatments for neuropathic pain.

Andrew S C Rice1, Raymond G Hill.   

Abstract

Existing treatments for neuropathic pain deliver inadequate pain relief, unacceptable side effects, or both. The unmet medical need for more effective treatment is driving a large volume of research to discover new drugs. Most existing treatments are drugs introduced to treat other pain conditions or other medical conditions, such as antidepressants and anticonvulsants, which were found empirically to be effective for neuropathic pain. Only recently have drug discovery efforts have become mechanistically driven, addressing targets identified by a molecular neurobiological approach to the pathophysiology of neuropathic states.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16409165     DOI: 10.1146/annurev.med.57.121304.131324

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  16 in total

1.  Discovery of diphenyl amine based sodium channel blockers, effective against hNav1.2.

Authors:  Debjani P Hudgens; Catherine Taylor; Timothy W Batts; Manoj K Patel; Milton L Brown
Journal:  Bioorg Med Chem       Date:  2006-10-10       Impact factor: 3.641

2.  Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity.

Authors:  I J Lever; T M Pheby; A S C Rice
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

3.  Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent NaV1.7 inhibitors.

Authors:  Brian A Sparling; S Yi; J Able; H Bregman; Erin F DiMauro; R S Foti; H Gao; A Guzman-Perez; H Huang; M Jarosh; T Kornecook; J Ligutti; B C Milgram; B D Moyer; B Youngblood; V L Yu; M M Weiss
Journal:  Medchemcomm       Date:  2016-12-02       Impact factor: 3.597

Review 4.  The Na(V)1.7 sodium channel: from molecule to man.

Authors:  Sulayman D Dib-Hajj; Yang Yang; Joel A Black; Stephen G Waxman
Journal:  Nat Rev Neurosci       Date:  2012-12-12       Impact factor: 34.870

Review 5.  Predictive validity of behavioural animal models for chronic pain.

Authors:  Odd-Geir Berge
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  Pregabalin as mono- or add-on therapy for patients with refractory chronic neuropathic pain: a post-marketing prescription-event monitoring study.

Authors:  Christian Lampl; Christine Schweiger; Bernhard Haider; Anita Lechner
Journal:  J Neurol       Date:  2010-03-11       Impact factor: 4.849

7.  The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain.

Authors:  Annemarie Ledeboer; Tongyao Liu; Jennifer A Shumilla; John H Mahoney; Sharmila Vijay; Matthew I Gross; Joseph A Vargas; Lance Sultzbaugh; Mark D Claypool; Laura M Sanftner; Linda R Watkins; Kirk W Johnson
Journal:  Neuron Glia Biol       Date:  2006-11

Review 8.  The use of viral gene transfer in studies of brainstem noradrenergic and serotonergic neurons.

Authors:  S Kasparov; A G Teschemacher
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-09-12       Impact factor: 6.237

9.  Fascin-1 Contributes to Neuropathic Pain by Promoting Inflammation in Rat Spinal Cord.

Authors:  Binbin Wang; Bingbing Fan; Qijun Dai; Xingguo Xu; Peipei Jiang; Lin Zhu; Haifeng Dai; Zhigang Yao; Zhongling Xu; Xiaojuan Liu
Journal:  Neurochem Res       Date:  2017-10-19       Impact factor: 3.996

10.  A pore-blocking hydrophobic motif at the cytoplasmic aperture of the closed-state Nav1.7 channel is disrupted by the erythromelalgia-associated F1449V mutation.

Authors:  Angelika Lampert; Andrias O O'Reilly; Sulayman D Dib-Hajj; Lynda Tyrrell; B A Wallace; Stephen G Waxman
Journal:  J Biol Chem       Date:  2008-06-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.